p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. - Wikidata - awgldk - TriplyDB

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

http://www.wikidata.org/entity/Q41731210

about

Contemporary murine models in preclinical astrocytoma drug development Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery.Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease.Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.Integrins and p53 pathways in glioblastoma resistance to temozolomide.Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma.Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

P2860

Q27026937-5FFC6879-1221-4E0A-875C-665FD8A31938 Q34447471-8EFAD652-306E-46D7-87DC-337E42177A63 Q34978253-52436EC9-D9EC-4EBE-ADC8-7D0006243EAE Q35086666-A1B9A563-A8E0-42EE-8241-B805061A71CD Q36782143-AF2C6230-5A76-4E09-9D56-831C34947C2C Q37412251-0146514C-39EB-4530-88D6-80D0F88AF4F6 Q37533648-42814DD7-900D-42F6-92E0-8CDBA3069DEC Q37804933-048EB0BD-E4D0-4131-B437-BEFB8ACFBF90 Q37874926-C0C52FEB-4346-408F-8B55-36E279487168 Q38261426-3BE88FBC-6E04-4EC0-9DCB-A64969D4C51A Q38709582-84D5A056-2E57-485B-A38D-7FFCCC0FFDE2 Q39232535-60F17620-2078-48AF-93F3-D158B5D2DC6A Q41098467-820021B3-57AB-4639-A1A1-BBF8AAE81868 Q41460271-626D4640-5FDD-4085-BB61-E5A69CD3180F Q41630032-F2253084-B53A-43C7-91B1-218DFDB0A2EF Q42689844-D36EF5A3-DCE4-4551-9E5B-0C2A46D6A410 Q43051079-85C3EB99-DC2C-4CC6-998F-D82E38FBCC45 Q48145832-1A347FCA-9E73-4BB7-9589-670C2560A0DE

P2860

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

http://www.wikidata.org/entity/Q41731210

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

p53 Small-molecule inhibitor e ...... anial glioblastoma xenografts.

@en

type

label

p53 Small-molecule inhibitor e ...... anial glioblastoma xenografts.

@en

prefLabel

p53 Small-molecule inhibitor e ...... anial glioblastoma xenografts.

@en

P1433

Q41731210-1B3B1ECC-C4B3-48A0-8B54-E69972CC4D11

P1476

Q41731210-EE49DDCF-8F7B-4307-B9A9-537A7393C9BB

P2093

Q41731210-168D8FFF-D8DC-4911-A97C-26A6EBD309B1

Q41731210-180CB65A-55E4-4A30-9300-EC7927086551

Q41731210-19ED3428-7E67-4E67-AA81-4639C45E95FE

Q41731210-2E0A99E6-DA87-4384-9B0E-A56EA7B44ACD

Q41731210-4175A1E7-A13A-4513-9BB3-E4FD0CEEDB56

Q41731210-71861842-29F8-40E5-9DA4-49CD6DAB9AC4

Q41731210-E38EF5D3-16F7-4640-AD93-DCE943323342

Q41731210-F5B442D7-EBBC-412F-A80C-98F6E94C411D

Q41731210-FDF9CBD6-305E-41E5-80F0-9F95D8A9BAB3

P2860

Q41731210-07B25C17-E102-43EF-955B-2A458A0BF39C

Q41731210-0C3FC634-EEF0-4D37-A714-ECC08E5463D1

Q41731210-14E6528F-3970-4969-AEB3-502977A16EE3

Q41731210-2CBE3D68-EA8E-4FA0-BCC4-BBD2DF7AC8DA

Q41731210-30BCEE3C-6032-4E5C-8310-7E0AB6C560CD

Q41731210-6155165C-33B6-4286-ACBD-5BA8F5875450

Q41731210-701078B8-806C-4FAB-ADC3-5C91810C3FD7

Q41731210-704F9245-B09C-47BB-98FE-7945A5AB01CC

Q41731210-75BA0453-CDA1-4DC0-B006-9E193C8679AA

Q41731210-83F0F9DD-4705-412C-8060-742DA340C0D1

P304

Q41731210-34C2D6DD-8541-470F-A299-5663132E2F19

P31

Q41731210-985ABC98-D82E-4B5E-A588-34C7A8124D92

P356

Q41731210-25D59F2A-9980-44D6-A1FD-49F6CF2E1C88

P407

Q41731210-C377A640-195B-4137-AF91-5FD5561AF818

P433

Q41731210-186C1FF6-0257-44C1-9453-FF81D417782B

P478

Q41731210-E20C4213-B173-4118-9674-839586BE3D89

P577

Q41731210-289E77F4-5A45-4684-BA56-54D9B2EC897D

P5875

Q41731210-BA52F497-BC7A-429B-8D04-099D142191EE

P698

Q41731210-DC93459A-D26E-4811-A3F1-9E2812D2C13B

P921

Q41731210-38599E3E-7121-4159-A0FB-74BA1537819A

P932

Q41731210-E646E276-AD26-4770-9E2A-27FA8EB35029

P356

0008-5472.CAN-08-1687

P1433

Cancer Research

P1476

p53 Small-molecule inhibitor e ...... anial glioblastoma xenografts.

@en

P2093

C David James

http://www.w3.org/2001/XMLSchema#string

Daphne A Haas-Kogan

http://www.w3.org/2001/XMLSchema#string

Eduard B Dinca

http://www.w3.org/2001/XMLSchema#string

Jann N Sarkaria

http://www.w3.org/2001/XMLSchema#string

Kan V Lu

http://www.w3.org/2001/XMLSchema#string

Michael D Prados

http://www.w3.org/2001/XMLSchema#string

Mitchel S Berger

http://www.w3.org/2001/XMLSchema#string

Russell O Pieper

http://www.w3.org/2001/XMLSchema#string

Scott R Vandenberg

http://www.w3.org/2001/XMLSchema#string

P2860

p53 mutations in human cancers

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.

Genetic pathways to primary and secondary glioblastoma

p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?

Classic and novel roles of p53: prospects for anticancer therapy.

Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.

O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells.

The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions.

Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells.

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

P304

10034-10039

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-1687

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23655765

http://www.w3.org/2001/XMLSchema#string

P698

19074867

http://www.w3.org/2001/XMLSchema#string

P921

P932

2987557

http://www.w3.org/2001/XMLSchema#string